Home

Articles from Marea Therapeutics, Inc.

Marea Therapeutics Appoints Shishir Gadam, Ph.D., as Chief Technical Officer
Marea Therapeutics, Inc., a clinical-stage biotechnology company harnessing the latest advances in human genetics to develop first-in-class, next-generation medicines for cardioendocrine diseases, today announced the appointment of Shishir Gadam, Ph.D., as chief technical officer. Dr. Gadam has extensive experience in the biotechnology industry and brings deep expertise and leadership in biologics development and manufacturing to Marea Therapeutics.
By Marea Therapeutics, Inc. · Via Business Wire · July 1, 2025
Marea Therapeutics Announces Oral Presentation Related to Acromegaly Program at ENDO 2025
Marea Therapeutics, Inc., a clinical-stage biotechnology company harnessing the latest advances in human genetics to develop first-in-class, next-generation medicines for cardioendocrine diseases, today announced an upcoming oral presentation related to MAR002, the company’s potential first-in-class, anti-growth hormone receptor (GHR) antibody being developed for acromegaly, at the 2025 Annual Meeting of the Endocrine Society (ENDO), being held from July 12-15, 2025 in San Francisco, CA.
By Marea Therapeutics, Inc. · Via Business Wire · June 24, 2025
Marea Therapeutics Appoints Charmi Turner as Senior Vice President, People & Culture
Marea Therapeutics, Inc., a clinical-stage biotechnology company harnessing the latest advances in human genetics to develop first-in-class, next-generation medicines for cardioendocrine diseases, today announced the appointment of Charmi Turner as senior vice president, people & culture. Charmi is an experienced life sciences industry human resources executive who brings deep expertise in leadership development and organizational alignment to Marea Therapeutics.
By Marea Therapeutics, Inc. · Via Business Wire · May 20, 2025
Marea Therapeutics Announces Publication in The Lancet of Positive Data from Phase 2a Clinical Trial of MAR001 for Cardiovascular Disease
Marea Therapeutics, Inc., a clinical-stage biotechnology company harnessing the latest advances in human genetics to develop first-in-class, next-generation medicines for cardioendocrine diseases, today announced that positive results from a Phase 2a clinical trial of MAR001 were published in The Lancet entitled “Safety and efficacy of a novel ANGPTL4 inhibitory antibody for lipid lowering: results from phase 1 and phase 1b/2a clinical studies.” The publication follows a recent late-breaking oral presentation of the Phase 2a results at the 93rd EAS Congress and can be accessed here. In addition, Marea announced a publication of MAR001 preclinical results in the peer-reviewed journal eBioMedicine entitled “A Novel ANGPTL4 Inhibitory Antibody Safely Improves Lipid Profiles in Non-Human Primates.” The publication can be accessed here.
By Marea Therapeutics, Inc. · Via Business Wire · May 16, 2025
Marea Therapeutics Presents Positive Data from Phase 2a Clinical Trial of MAR001, Being Developed for Cardiovascular Disease, in Late-Breaking Oral Session at the 93rd EAS Congress
Marea Therapeutics, Inc., a clinical-stage biotechnology company harnessing the latest advances in human genetics to develop first-in-class, next-generation medicines for cardioendocrine diseases, today presented positive data from a Phase 2a clinical trial of MAR001 in a late-breaking oral session at the 93rd European Atherosclerosis Society (EAS) Congress being held May 4-7, 2025 in Glasgow, UK. MAR001 is a first-in-class monoclonal antibody that targets ANGPTL4, a protein that is highly expressed in adipose tissue.
By Marea Therapeutics, Inc. · Via Business Wire · May 7, 2025
Marea Therapeutics Announces Late-Breaking Oral Presentation at the 93rd EAS Congress
Marea Therapeutics, Inc., a clinical-stage biotechnology company harnessing the latest advances in human genetics to develop first-in-class, next-generation medicines for cardioendocrine diseases, today announced two upcoming presentations at the 93rd European Atherosclerosis Society (EAS) Congress being held May 4-7, 2025 in Glasgow, UK.
By Marea Therapeutics, Inc. · Via Business Wire · April 15, 2025
Marea Therapeutics Forms Clinical Scientific Advisory Board
Marea Therapeutics, Inc., a clinical-stage biotechnology company harnessing the latest advances in human genetics to develop first-in-class, next-generation medicines for cardiometabolic diseases, today announced the formation of a clinical scientific advisory board (SAB) consisting of leading experts in drug development and cardiometabolic diseases.
By Marea Therapeutics, Inc. · Via Business Wire · January 21, 2025
Marea Therapeutics Provides Update on Corporate Progress Including Positive Topline Results from Phase 2a Clinical Trial of MAR001 for Cardiovascular Disease and Disclosure of Second Lead Pipeline Program for the Treatment of Acromegaly
Marea Therapeutics, Inc., a clinical-stage biotechnology company harnessing the latest advances in human genetics to develop first-in-class, next-generation medicines for cardio-endocrine diseases, today provided an update on the company’s recent progress and upcoming milestones for 2025 in advance of the J.P. Morgan 43rd Annual Healthcare Conference, taking place from January 13-16, 2025 in San Francisco, CA.
By Marea Therapeutics, Inc. · Via Business Wire · January 9, 2025
Marea Therapeutics Expands Management Team and Board of Directors
Marea Therapeutics, Inc., a clinical-stage biotechnology company harnessing the latest advances in human genetics to develop first-in-class, next-generation medicines for cardiometabolic diseases, today announced additions to its management team and board of directors.
By Marea Therapeutics, Inc. · Via Business Wire · December 19, 2024